Foghorn Therapeutics, Inc.

Contributing Author

Recent Articles by Foghorn Therapeutics, Inc.

Feb-03	Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit FHTX GlobeNewswire
Jan-13	Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium FHTX -5.54% FHTX GlobeNewswire
Jan-09	Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 FHTX GlobeNewswire
Nov-25	Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference FHTX GlobeNewswire
Nov-05	Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update FHTX +13.31% GlobeNewswire
Nov-03	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences FHTX GlobeNewswire
Oct-30	Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs FHTX GlobeNewswire
Oct-16	Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit FHTX GlobeNewswire
Aug-27	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences FHTX GlobeNewswire
Aug-05	Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update FHTX GlobeNewswire
May-22	Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences FHTX GlobeNewswire
May-14	Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update FHTX -5.08% GlobeNewswire
May-05	Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference FHTX -8.49% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.